Fig. 1: Observed mean changes from baseline for the primary domains of interest (PRO-evaluable population). | Leukemia

Fig. 1: Observed mean changes from baseline for the primary domains of interest (PRO-evaluable population).

From: Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Fig. 1

A FACT-G PWB. B FACT-LeuS. C FACT-Leu TOI. D FACT-G total score. E FACT-Leu total score. F EQ-VAS. MID thresholds for improvement and worsening are shown as dotted lines. Data up to C13D1 (the latest visit at which n was ≥10 in both arms) and at EOT were included. C cycle, CI confidence interval, D day, EOT end of treatment, EQ-VAS EuroQol visual analogue scale, FACT-G Functional Assessment of Cancer Therapy–General, FACT-Leu Functional Assessment of Cancer Therapy–Leukemia, LeuS leukemia “additional concerns” subscale, MID minimal important difference, PRO patient-reported outcome, PWB physical well-being, TOI trial outcome index.

Back to article page